A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Clinical trial NCT05051891 · COMPLETED
Trial details
- NCT number
- NCT05051891
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-22
- Primary completion
- 2025-06-30
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.